Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INX-315 in Advanced Cancer
NCT05735080Phase 2Recruiting
- Sponsor
- Incyclix Bio
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of INX-315 in breast cancer, ovarian cancer, solid tumor, sponsored by Incyclix Bio. Started Mar 2023; status: recruiting.
02
Drugs
INX-315
03
Conditions
breast cancerovarian cancersolid tumor
Beyond the preview
Go deeper on NCT05735080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735080.